News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RedHill Biopharma Ltd. Acquires Exclusive Rights to a MAP Bacterium Companion Diagnostic Test for its RHB-104 (Crohn’s) Drug



9/22/2011 10:08:30 AM

TEL AVIV, Israel--(BUSINESS WIRE)--RedHill Biopharma Ltd. (TASE: RDHL), an emerging Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical-stage new formulations of existing drugs, announced the acquisition of an exclusive license from the University of Central Florida Research Foundation, Inc. (UCF) to a patent-protected diagnostic test for the detection of the MAP bacterium (Mycobacterium avium paratuberculosis). MAP is estimated to be found in 40%-50% of patients who suffer from Crohn’s disease - an inflammatory disorder of the gastrointestinal tract, affecting approximately 700,000 patients in the US alone, with currently no available cure.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES